Evaluation of amifostine for protection against cisplatin-induced serious hearing loss in children treated for average-risk or high-risk medulloblastoma

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 848-855

  Gurney, James G ^a,i,j   Bass, Johnnie K ^a   Onar Thomas, Arzu ^a   Huang, Jie ^a   Chintagumpala, Murali ^b   Bouffet, Eric ^c   Hassall, Tim ^c   Gururangan, Sridharan ^d   Heath, John A ^e   Kellie, Stewart ^f   Cohn, Richard ^g   Fisher, Michael J ^h   Panandiker, Atmaram Pai ^a   Merchant, Thomas E ^a   Srinivasan, Ashok ^a   Wetmore, Cynthia ^a   Qaddoumi, Ibrahim ^a   Stewart, Clinton F ^a   Armstrong, Gregory T ^a   Broniscer, Alberto ^a   Gajjar, Amar ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d ROYAL CHILDREN'S HOSPITAL   (Australia)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

^f ROYAL CHILDREN'S HOSPITAL   (Australia)

^g CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^h SYDNEY CHILDREN'S HOSPITAL   (Australia)

ⁱ CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^j UNIVERSITY OF MEMPHIS   (United States)

more..

Author keywords

audiology; brain neoplasms; late effects; ototoxicity; platinum drugs

Indexed keywords

AMIFOSTINE; CISPLATIN; ANTINEOPLASTIC AGENT; PROTECTIVE AGENT;

ARTICLE; CANCER PATIENT; CHANG OTOTOXICITY SCALE; CHILD; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; HEARING AID; HEARING IMPAIRMENT; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; OTOTOXICITY; RATING SCALE; ADOLESCENT; CEREBELLAR NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; HEARING LOSS; PRESCHOOL CHILD; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; AMIFOSTINE; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CISPLATIN; FEMALE; HEARING LOSS; HUMANS; MALE; MEDULLOBLASTOMA; PROTECTIVE AGENTS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901014439     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not241     Document Type: Article

References (30)

1. Orgel E, Jain S, Ji L, et al. Hearing loss among survivors of childhood brain tumors treated with an irradiation-sparing approach. Pediatr Blood Cancer. 2012;58:953-958.
2. Lafay-Cousin L, PurdyE,HuangA, etal. Early cisplatin inducedototoxicity profile may predict the need for hearing support in children with medulloblastoma. Pediatr Blood Cancer. 2013;60:287-292.
3. Brock PR, Knight KR, Freyer DR, et al. Platinum-induced ototoxicity in children: a consensus review on mechanisms, predisposition, and protection, including a new International Society of Pediatric Oncology Boston Ototoxicity Scale. J Clin Oncol. 2012;30:2408-2417.
4. Van Der Hulst RJAM, Dreschler WA, Urbanus NAM. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives. Ann Otol Rhinol and Laryngol. 1998;97:133-137.
5. Li Y,Womer RB, Silber JH. Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose. Eur J Cancer. 2004;40: 2445-2451.
6. Gurney JG, Severson RK, Davis S, et al. Incidence of cancer in children in the United-States-sex-specific, race-specific, and 1-year age-specific rates by histologic type. Cancer. 1995;75:2186-2195.
7. Gilmer-Knight KR, Kraemer DF, Neuwelt EA. Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol. 2005;23:8588-8596.
8. Blakley BW, Cohen JI, Doolittle ND, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy: review and summary of the annual meeting of the Blood-Brain Barrier Disruption Program, Gleneden Beach, Oregon, March 10, 2001. Laryngoscope. 2002;112:1997-2001.
9. Rybak LP, Mukherjea D, Jajoo S, et al. Cisplatin ototoxicity and protection: clinical and experimental studies. Tohoku J Exp Med. 2009;219:177-186.
10. McKibbin T, Panetta JC, Fouladi M, et al. Clinical pharmacokinetics of amifostine and WR1065 in pediatric patients with medulloblastoma. Clin Cancer Res. 2010;16:1049-1057.
11. ChurchMW,BlakleyBW,BurgioDL,et al.WR-2721(Amifostine)ameliorates cisplatin-induced hearing loss but causes neurotoxicity in hamsters: dose-dependent effects. J Assoc Res Otolaryngol. 2004;5:227-237.
12. Hussain AE, Blakley BW, Nicolas M, et al. Assessment of the protective effects of amifostine against cisplatin-induced toxicity. J Otolaryngol. 2003;32:294-297.
13. Fisher MJ, Lange BJ, Needle MN, et al. Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer. 2004;43:780-784.
14. Gallegos-Castorena S, Martínez-Avalos A, Mohar-Betancourt A, et al. Toxicity prevention with amifostine in pediatric osteosarcoma patients treated with cisplatin and doxorubicin. Pediatr Hem Oncol. 2007;24: 403-408.
15. Katzenstein HM, Chang KW, Krailo M, et al. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. Cancer. 2009;115: 5828-5835.
16. Marina N, Chang KW, Malogolowkin M, et al. Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ-cell tumors: a Children's Oncology Group study. Cancer. 2005;104:841-847.
17. Fouladi M, Chintagumpala M, Ashley D, et al. Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol. 2008;26:3749-3755.
18. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-termresults from a prospective,multicentre trial. Lancet Oncol. 2006;7:813-820.
19. Chang CH, Housepian EM, HerbertCJr.Anoperative staging systemand amegavoltage radiotherapeutic technic forcerebellarmedulloblastomas. Radiology. 1969;93:1351-1359.
20. Gurney JG, Bass JK. New International Society of Pediatric Oncology Boston Ototoxicity Grading Scale for pediatric oncology: still room for improvement. J Clin Oncol. 2012;30:2303-2306.
21. ChangKW, Chinosornvatana N. Practical grading system for evaluating cisplatin ototoxicity in children. J Clin Oncol. 2010;28:1788-1795.
22. Chang KW. Clinically accurate assessment and grading of ototoxicity. Laryngoscope. 2011;121:2649-2657.
23. Rednam S, Scheurer ME, Adesina A, et al. Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma. Pediatr Blood Cancer. 2013;60: 593-598.
24. van As JW, van den Berg H, van Dalen EC. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer. Cochrane Database Syst Rev. 2012;5:1-39, CD009219.
25. BrockPR,BellmanSC,YeomansEC, etal.Cisplatinototoxicityinchildren:a practical grading system. Med Pediatr Oncol. 1991;19:295-300.
26. Freyer DR, Sung L, Reaman GH. Prevention of hearing loss in children receiving cisplatin chemotherapy. J Clin Oncol. 2009;27:317-318.
27. Bertolini P, Lassalle M, Mercier G, et al. Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J PediatrHematol Oncol. 2004;26:649-655.
28. Einarsson EJ, PetersenH,Wiebe T, et al. Long termhearing degeneration after platinum-basedchemotherapy in childhood. Int JAudiology. 2010; 49:765-771.
29. Grau C, Overgaard J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys. 1996;36:515-517.
30. HoWK,WeiWI,KwongDL, et al. Long-termsensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck. 1999;21:547-553.